Stockreport

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Annexon, Inc. - common stock  (ANNX) 
PDF Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atro [Read more]